Business
Zanidatamab Data Highlight Durable Antitumor Activity in HER2‑Expressing Biliary Tract and Gastroesophageal Cancers at ASCO Gastrointestinal Cancers Symposium
Durable Responses Observed in Refractory Biliary Tract Cancer (BTC) and Gastroesophageal (GEA) Cancers Enrollment Continues for Zanidatamab Global Pivotal
About this update from Zymeworks Inc.
[{"type":"text","content":"\n\nDurable Responses Observed in Refractory Biliary Tract Cancer (BTC) and Gastroesophageal (GEA) Cancers\n\n\nEnrollment Continues for Zanidatamab Global Pivotal Trial in BTC; Global Pivotal Trial in First-Line GEA Slated to Open in Mid-2021\n\n\n VANCOUVER, British Columbia--(BUSINESS WIRE)--\nZymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced new and updated clinical data for the HER2‑targeted bispecific antibody zanidatamab, in both HER2-expressing biliary tract cancer (BTC) and gastroesophageal adenocarcinoma (GEA). The data are being presented today at the American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium, taking place virtually January 15 – 17, 2021.\nThis press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210115005163/en/\n“Data presented today at ASCO GI continue to demonstrate the potential of zanidatamab in advanced HER2-expressing cancers with high unmet need. The response rates and median duration of response in refractory BTC and GEA compare favorably to current standard of care and emerging treatments,” said Diana Hausman, M.D., Chief Medical Officer at Zymeworks. “The BTC data were the basis of the recent Breakthrough Therapy designation granted by the FDA, a key step in helping zanidatamab become the first potential HER2‑targeted therapy approved in this indication. Furthermore, the activity in GEA supports our goal of establishing zanidatamab as the foundational HER2-targeted therapy for GEA and other HER2-positive cancers, not only in later stage disease, but also in earlier lines of treatment.”\n\nThe following presentations are available to conference registrants on the ASCO conference website as well as to the general public at ir.zymeworks.com/events-and-presentations/.\n\nZanidatamab Monotherapy and Chemotherapy Combinations in HER2-Expressing Gastroesophageal Cancer – Clinical Results – Abstract #164\n\nZanidatamab (ZW25) in HER2-expressing gastroesophageal adenocarcinoma (GEA): Results from a Phase 1 study (Presenter: Funda Meric-Bernstam, MD, UT MD Anderson Cancer Center, TX; Rapid Abstract oral presentation on Friday, January 15, 11:30 am-12:15 pm ET)\n\nHER2 is overexpressed in approximately 20% of GEA patients. For these patients, trastu...